Tracking myasthenia gravis symptoms on rozanolixizumab treatment
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed diagnosis of generalized myasthenia gravis with positive antibody test (anti-AChR or anti-MUSK)
- Moderate to severe symptoms (MG-ADL score of 3 or higher, with at least some symptoms beyond eye weakness)
- Haven't received rozanolixizumab before, or last dose was more than 3 months ago
- Current blood protein level (IgG) of at least 5.5 g/L
- All required vaccinations completed and able to understand and sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study continues treatment for children who took part in an earlier trial (MG0006) for generalized myasthenia gravis. It tests 6-week cycles of a drug called rozanolixizumab to see if it continues to work well and stay safe.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
This study is for people with generalized myasthenia gravis who are already on ravulizumab and a daily steroid. It aims to see if the steroid dose can be safely lowered over time.
This study tests a new drug called SHR-2173 to help people with generalized myasthenia gravis (a condition where muscles weaken because the immune system blocks communication between nerves and muscles). The drug is designed to work with treatments you're already taking to improve muscle strength and reduce symptoms.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.